Engineered immune cells take aim at Hard-to-Treat leukemia
NCT ID NCT06325748
First seen Feb 13, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This early-phase study tests SENTI-202, a ready-made immune cell therapy, in people with certain blood cancers (like AML and MDS) that have come back or not responded to treatment. The therapy uses specially designed natural killer (NK) cells to find and attack cancer cells while sparing healthy ones. The main goals are to check safety and find the best dose, with a small group of 21 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML/MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Methodist Healthcare
San Antonio, Texas, 78229, United States
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
TriStar Bone Marrow Transplant
Nashville, Tennessee, 37203, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.